SGLT2抑制剂在2型糖尿病合并阿尔茨海默病中作用的研究进展

Research progress of the effect of sodium glucose cotransporter 2 inhibitors in Alzheimer's disease

钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)2抑制剂不仅广泛应用于糖尿病的治疗,还在多项动物试验及临床试验中表现出预防动脉粥样硬化、改善认知障碍等作用,有望改善2型糖尿病合并阿尔茨海默病患者的预后。其机制包括抗炎、增加脑源性神经营养因子、抑制乙酰胆碱酯酶、减轻氧化应激和改善线粒体功能障碍、恢复分解代谢和合成代谢之间的平衡等。

Sodium dependent glucose transporters(SGLT)-2 inhibitors are not only widely used in the treatment of diabetes,but also have shown the role of preventing atherosclerosis and improving cognitive impairment in many animal and clinical trials,which is expected to improve the prognosis of type 2 diabetes patients with Alzheimer's disease.Its mechanisms include anti inflammation,increasing brain-derived neurotrophic factor,inhibiting acetylcholinesterase,alleviating oxidative stress and improving mitochondrial dysfunction,restoring the balance between catabolism and anabolism,etc.